Editas Medicine, Inc. (EDIT)
|Net Income (ttm)||-134.98M|
|Trading Day||May 7|
|Day's Range||34.05 - 36.79|
|52-Week Range||23.51 - 99.95|
Editas (EDIT) reports wider-than-expected loss in the first quarter of 2021 while revenues beat estimates. Pipeline development remains in focus for the company.
Editas (EDIT) delivered earnings and revenue surprises of -13.16% and 2.96%, respectively, for the quarter ended March 2021. Do the numbers hold clues to what lies ahead for the stock?
Strengthening Leadership by Adding Mark S. Shearman, Ph.D., as Chief Scientific Officer
CAMBRIDGE, Mass., May 05, 2021 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (Nasdaq: EDIT), a leading genome editing company, today announced that it named Mark S. Shearman, Ph.D., as the Company's Executi...
With the trading day more than halfway over, the broad markets were getting crushed.
Editas Medicine to Present Preclinical Data Demonstrating Progress in Development of Gene Editing Medicines for the T...
CAMBRIDGE, Mass., May 04, 2021 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (Nasdaq: EDIT), a leading genome editing company, today announced three presentations, including one from a research collaboratio...
Editas Medicine to Present Preclinical Data Demonstrating Advancements in In Vivo Gene Editing Approach for the Treat...
Preclinical data support novel approaches for the treatment of Usher Syndrome 2A and retinitis pigmentosa 4 Preclinical data support novel approaches for the treatment of Usher Syndrome 2A and retinitis...
CAMBRIDGE, Mass., April 28, 2021 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (Nasdaq: EDIT), a leading genome editing company, today announced that it will host a conference call and webcast on Wednesday,...
On Editas' (EDIT) first-quarter earnings call, investor focus is expected to be on the company's progress with the development of its lead pipeline candidate - EDIT-101.
A "sell" rating is one thing, but a price target barely half of the Thursday close? It's no wonder Editas stock is crashing, and taking other gene-editing stocks with it.
Investors are trying to figure out which stocks have the best prospects.
Investors are running for the hills following this analyst take on the biotech's prospects.
Goldman says Editas' clinical data may underwhelm. We don't agree.
Regulatory and drug-pricing worries have knocked biotech stocks off their Covid-19 pedestal. After hitting a high point in early February, biotech stocks have collectedly fallen 21%.
The biotech space is on the verge of hypergrowth, thanks to a scientific breakthrough in genetic editing. This is your ultimate guide to understanding and profiting from CRISPR stocks.
Our indicative theme of Gene Editing stocks is down by about 19% year-to-date, compared to the S&P 500 which is up by about 6% over the same period. With the economic recovery expected to gather pace, o...
All three of these stocks appear to be great comeback candidates.
Editas (EDIT) reported earnings 30 days ago. What's next for the stock?
Gene editing stocks are on the move Wednesday with investors taking extra interest in biotech companies on news from two major players. The post Gene Editing Stocks: What BLUE, NTLA, BEAM, CRSP and EDIT...
A strong overall stock market performance is lifting the biotech stock.
Our indicative theme of Gene Editing stocks is down by about 24% year-to-date, compared to the S&P 500 which has remained almost flat over the same period. The recent sell-off comes on the back of risin...
Insider buying can be an encouraging signal for potential investors, especially when markets face uncertainty. A pair of chief executives and an executive board chair were among the insiders making purc...
Short-term issues shouldn't affect long-term investors.
The stock was pulled down by the undertow of the broader market sell-off.
With the trading day about halfway over, the broad markets came roaring back to start out the week.
With the trading day more than halfway over, the broad markets recovered slightly from Thursday's downturn, with the exception of the Dow Jones industrial average.
ARK Investment Management – or ARK Invest, as it usually styles itself – had a great 2020. ARK Innovation ETF (ARKK), the firm's flagship fund, returned more than 150% last year.
Editas (EDIT) reports wider-than-expected loss in the fourth quarter of 2020 while revenues beat estimates. Pipeline development a key focus for the company.
After a huge run-up in valuation, investors are a little spooked.
Turnover at the top of a company can be troubling. But it can sometimes be a good thing.
Editas Medicine to Host Conference Call Discussing Fourth Quarter and Full Year 2020 Results and Corporate Update
CAMBRIDGE, Mass., Feb. 18, 2021 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (Nasdaq: EDIT), a leading genome editing company, today announced that it will host a conference call and webcast on Thursday, F...
Editas (EDIT) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
In a field that's becoming more crowded, what will set Editas apart?
On Editas' (EDIT) fourth-quarter earnings call, investor focus will be on the company's progress with the development of its CRISPR-based experimental candidate, EDIT-101.
Editas Medicine (EDIT) closed the most recent trading day at $57.94, moving +1.35% from the previous trading session.
As more young investors take up day trading, I have a recipe for long-term wealth creation
Investors reacted negatively to a major deal announced by Editas' former partner with another gene-editing biotech.
Which of these two hot gene therapy stocks is the better buy?
In the latest trading session, Editas Medicine (EDIT) closed at $63.18, marking a +1.64% move from the previous day.
Gene-editing technology is used to insert, edit, or delete a gene from an organism's genome, and shows promise in treating medical conditions ranging from cancer to rare genetic conditions. Our indicati...
Could this maverick biotech discover the cure for several debilitating rare diseases?
In the latest trading session, Editas Medicine (EDIT) closed at $65.47, marking a -0.44% move from the previous day.
Editas Medicine, a biotechnology company focused on developing treatments using gene editing technology, has plunged by 13% over the last 5 trading days, after the company stated its plans to issue 3.5 ...
Editas Medicine, Inc., a clinical stage genome editing company, focuses on developing transformative genomic medicines to treat a range of serious diseases. It develops a proprietary genome editing platform based on CRISPR technology to target genetically addressable diseases and therapeutic areas. The company develops EDIT-101, which is in Phase 1/2 clinical trial for Leber Congenital Amaurosis type 10, a genetic form of vision loss that leads to blindness in childhood. It also develops EDIT-102 for the treatment of Usher Syndrome 2A, which is... [Read more...]
|IPO Date |
Feb 3, 2016
|Stock Exchange |
|Ticker Symbol |
In 2020, EDIT's revenue was $90.73 million, an increase of 341.93% compared to the previous year's $20.53 million. Losses were -$115.98 million, -13.29% less than in 2019.
According to 12 analysts, the average rating for EDIT stock is "Buy." The 12-month stock price forecast is 47.67, which is an increase of 39.75% from the latest price.